Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about Oramed’s progress and future advances.
“Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications”
http://www.biotuesdays.com/features/2015/12/1/oramed-sees-value-creating-events-through-2016
